Effective treatment of gonorrhoea.
Effective therapy of gonorrhoea has changed drastically over the years, reflecting the progessive acquisition of relative antibiotic resistance by the causative organism. Although in the US. th 1974 USPHS recommendations are the best guidelines for management at present, recent epidemiological trends may obviate some of these provisions. The most important of these trends is the emergence of R-factor carrying strains capable of producing penicillinase, thereby making these strains absolutely resistant to clinically achievable levels of penicillin. This review analyses this problem in the context of reasonable therapeutic goals and also discusses optimum management of patients with such complications as pharyngeal infection, pelvic inflammatory disease and disseminated gonococcal infection.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006069:Gonorrhea / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007700:Kinetics; D008297:Male; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy / Q000209:etiology; D010403:Penicillin Resistance; D010406:Penicillins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D010608:Pharyngeal Diseases / Q000188:drug therapy; D000198:Spectinomycin / Q000627:therapeutic use; D013587:Syphilis / Q000150:complications / Q000188:drug therapy; D014526:Urethritis / Q000188:drug therapy / Q000209:etiology
D000900:Anti-Bacterial Agents; D010406:Penicillins; D000198:Spectinomycin